Sweden's SOBI Q2 revenue beats estimates on higher sales, portfolio expansion

Swedish Orphan Biovitrum AB (publ)

16/07/2026 07:12

Overview
Sweden biopharma's Q2 revenue rose 27% and beat analyst expectations
Adjusted EPS for Q2 increased year-over-year
Q2 EBIT missed analyst expectations

Outlook
Sobi raises 2026 revenue growth outlook to mid-to high-teens percentage at CER
Company lifts 2026 adjusted EBITA margin forecast to mid-to high-30s percentage of revenue

Result Drivers
HAEMATOLOGY GROWTH - Revenue in haematology rose 27% at CER, mainly due to higher sales of Altuvoct and Doptelet
IMMUNOLOGY GROWTH - Immunology revenue rose 37% at CER, supported by higher sales of Gamifant and Kineret
STRATEGIC PORTFOLIO EXPANSION - Revenue from the strategic portfolio grew 53% at CER

Company press release: ID:nWkr7SKy15

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
SEK 7.84 bln
SEK 7.29 bln (5 Analysts)
Q2 Adjusted EPS
 
SEK 3.17
 
Q2 EBIT
Miss
SEK 1.63 bln
SEK 1.79 bln (5 Analysts)
Q2 Adjusted Free Cash Flow
 
SEK 1.91 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Swedish Orphan Biovitrum AB (publ) is SEK495.00, about 8.6% above its July 15 closing price of SEK456.00
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)